(Q35840036)

10 August 2017

1 reference

title

Homocysteine, B-vitamin supplementation, and stroke prevention: from observational to interventional trials (English)

1 reference

10 August 2017

0 references

Yvonne Schwammenthal

1

1 reference

10 August 2017

David Tanne

series ordinal

2

1 reference

10 August 2017

publication date

1 August 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

493-495

1 reference

Update on cobalamin, folate, and homocysteine

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Hyperhomocyst(e)inemia and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Plasma homocysteine levels and mortality in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Serum total homocysteine and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/L

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Effect of folic acid fortification of food on homocysteine-related mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Use of ramipril in preventing stroke: double blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Decreased rate of coronary restenosis after lowering of plasma homocysteine levels

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900826-9

7 January 2021

10.1016/S1474-4422(04)00826-9

Identifiers

DOI

1 reference

10 August 2017

1 reference